This presentation will provide an update since the first disclosure of ertugliflozin (PF-04971729) at the 2010 American Chemical Society national meeting held in Boston; particular emphasis will be placed on the rapid progression of ertugliflozin in the early phases of development, from first in human (FIH) to successful completion of phase 2 trials. Ertugliflozin is Phase 3 ready, with trials expected to begin later in 2013, and is being evaluated for the treatment of type 2 diabetes.

From PF-04971729 to ertugliflozin: An overview of the progression of Pfizer's SGLT2 inhibitor program from FIH to successful POC

246th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.